EDIT sentiment intelligence

Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks

Tone

Neutral 50/100

Event

Earnings

Published

13 Jul 2026 12:30

Source

Market source

Editas Medicine stock holds the line as pipeline work continues.

Editas Medicine remains focused on its gene-editing pipeline and Nasdaq listing, emphasizing clinical progress and regulatory milestones. As a clinical-stage company, its value is tied to development updates and balance-sheet durability, rather than immediate sales. Investors mon

Tone

Neutral 50/100

Event

Regulatory and legal

Published

03 Jul 2026 19:13

Source

Ad-hoc-news.de

Editas Medicine, Inc.(NasdaqGS: EDIT) added to Russell 2500 Growth Benchmark

Editas Medicine, Inc. (NasdaqGS: EDIT) has been added to the Russell 2500 Growth Benchmark. This news follows a series of recent announcements, including the company's inclusion in several other Russell benchmarks and updates on its preclinical data for EDIT-401 for hyperlipidemi

Tone

Neutral 50/100

Event

Market update

Published

29 Jun 2026 19:40

Source

www.marketscreener.com

Price to sales forward of Editas Medicine, Inc. – NASDAQ:EDIT

This article provides financial information for Editas Medicine, Inc. (NASDAQ: EDIT), specifically focusing on its forward price-to-sales ratio. It details where the data is sourced from, including ICE Data Services and FactSet, and notes that the information is provided by Tradi

Tone

Neutral 50/100

Event

Market update

Published

28 Jun 2026 04:09

Source

TradingView

Enterprise value to EBITDA forward of Editas Medicine, Inc. – NASDAQ:EDIT

This article displays the forward Enterprise Value to EBITDA for Editas Medicine, Inc. (NASDAQ: EDIT). It presents basic financial and market information related to the company, indicating that the market was closed at the time of the data display. The page is sourced from Tradin

Tone

Neutral 50/100

Event

Market update

Published

27 Jun 2026 14:42

Source

TradingView

Price to earnings forward of Editas Medicine, Inc. – LSE:0IFK

This article provides financial information for Editas Medicine, Inc. (LSE:0IFK), specifically focusing on its forward price-to-earnings ratio. The content appears to be a stub or a data point from a financial platform, showing the company's identifier on the London Stock Exchang

Tone

Neutral 50/100

Event

Earnings

Published

27 Jun 2026 09:42

Source

TradingView

Price to book forward of Editas Medicine, Inc. – NASDAQ:EDIT

This article displays the "Price to book forward" financial metric for Editas Medicine, Inc. (NASDAQ: EDIT). It presents a value for a specific period and notes any changes in that value, but does not provide additional details or analysis. The content appears to be a stub or a d

Tone

Neutral 50/100

Event

Market update

Published

27 Jun 2026 04:10

Source

TradingView

Enterprise value to EBITDA forward of Editas Medicine, Inc. – LSE:0IFK

This article provides financial information for Editas Medicine, Inc. (LSE:0IFK), specifically focusing on its Enterprise Value to EBITDA (EV/EBITDA) forward metric. It appears to be a financial data page from TradingView, displaying market status and a link to detailed financial

Tone

Neutral 50/100

Event

Market update

Published

27 Jun 2026 03:10

Source

TradingView

Editas Medicine, Inc. Actuals & Estimates (NASDAQ:EDIT)

This article provides an overview of Editas Medicine, Inc. (NASDAQ: EDIT) financial actuals and estimates, stock performance, and analyst forecasts. It details historical stock prices, market capitalization, volatility, and upcoming earnings reports, along with other financial st

Tone

Neutral 50/100

Event

Earnings

Published

27 Jun 2026 03:10

Source

TradingView

Editas Medicine, Inc. Actuals & Estimates (LSE:0IFK)

This article provides an overview of Editas Medicine, Inc. (LSE:0IFK) stock, including its current price, market capitalization, and historical performance. It also details financial actuals and estimates, analysts' price targets, and key financial metrics like earnings, revenue,

Tone

Neutral 50/100

Event

Earnings

Published

26 Jun 2026 18:09

Source

TradingView

EDIT Forecast — Price Target — Prediction for 2027

This article provides a forecast for Editas Medicine, Inc. (EDIT) stock, including analyst price targets, past performance, and key financial metrics. It highlights the stock's current price, market capitalization, and upcoming earnings report, while also addressing frequently as

Tone

Neutral 50/100

Event

Analyst action

Published

26 Jun 2026 14:09

Source

TradingView

Editas Medicine | 4: Statement of changes in beneficial ownership of securities-Director Hirsch Andrew

This document is a Form 4 filing for Editas Medicine, detailing changes in beneficial ownership of securities for Director Andrew Hirsch. Such filings are made with the SEC to report transactions by company insiders.

Tone

Neutral 50/100

Event

Market update

Published

24 Jun 2026 08:40

Source

Moomoo

Editas Medicine | 4: Statement of changes in beneficial ownership of securities-Director Hopfield Jessica

This article provides a Form 4 statement for Editas Medicine, detailing changes in beneficial ownership of securities for Director Jessica Hopfield. The document reports on transactions that have altered her holdings in the company.

Tone

Neutral 50/100

Event

Market update

Published

23 Jun 2026 20:11

Source

Moomoo

Editas Medicine (EDIT) director awarded 51,700 stock options at $2.55 strike

Editas Medicine, Inc. director David Scadden was granted 51,700 stock options with an exercise price of $2.55 per share, set to expire on June 16, 2036. The options were granted on June 17, 2026, and will vest in full on June 17, 2027. This transaction is a compensation-related a

Tone

Neutral 50/100

Event

Market update

Published

23 Jun 2026 20:11

Source

Stock Titan

Editas Medicine (NASDAQ: EDIT) director granted 51,700 stock options at $2.55

Editas Medicine director Jessica Hopfield was granted 51,700 stock options at an exercise price of $2.55 per share on June 17, 2026. These options are scheduled to vest in full on June 17, 2027, and will expire on June 16, 2036. This transaction was reported in a Form 4 filing an

Tone

Neutral 50/100

Event

Market update

Published

23 Jun 2026 09:10

Source

Stock Titan

Editas Medicine (EDIT) director Andrew Hirsch awarded 51,700 stock options

Editas Medicine director Andrew Hirsch was granted 51,700 stock options with an exercise price of $2.55 per share. These options, granted on June 17, 2026, are scheduled to fully vest on June 17, 2027, and expire on June 16, 2036. This grant serves as a compensation award, and no

Tone

Neutral 50/100

Event

Market update

Published

22 Jun 2026 20:41

Source

Stock Titan

[Form 4] Editas Medicine, Inc. Insider Trading Activity

Editas Medicine, Inc. director Bernadette Connaughton received a grant of 51,700 stock options with an exercise price of $2.55 per share, vesting fully on June 17, 2027, and expiring on June 16, 2036. This transaction is considered neutral in sentiment and filing impact, with no

Tone

Neutral 50/100

Event

Market update

Published

22 Jun 2026 20:40

Source

Stock Titan

Form 4 Editas Medicine For: 22 June By Investing.com

This article from Investing.com is a straightforward financial market update, primarily serving as a placeholder for a "Form 4" filing for Editas Medicine (EDIT) dated June 22. It briefly mentions the stock's performance on that day, showing a 4.09% increase. The content also inc

Tone

Neutral 50/100

Event

Market update

Published

22 Jun 2026 20:40

Source

Investing.com Canada

Editas Medicine (EDIT) director granted 51,700 stock options at $2.55 strike

Editas Medicine director Elliott M. Levy was granted 51,700 stock options with an exercise price of $2.55 per share on June 17, 2026. These options are scheduled to vest in full on June 17, 2027, and will expire on June 16, 2036. Following this grant, Levy holds 51,700 derivative

Tone

Neutral 50/100

Event

Market update

Published

22 Jun 2026 20:40

Source

Stock Titan

Editas Medicine elects two directors and ratifies auditor at annual meeting

Editas Medicine (NASDAQ:EDIT) held its 2026 Annual Meeting where shareholders elected Bernadette Connaughton and Elliott Levy as Class I directors and approved executive compensation on an advisory basis. Shareholders also ratified PricewaterhouseCoopers LLP as the independent re

Tone

Neutral 50/100

Event

Market update

Published

19 Jun 2026 13:11

Source

Investing.com

Editas Medicine (NASDAQ: EDIT) stockholders elect directors and ratify PwC at 2026 meeting

Editas Medicine (EDIT) held its 2026 annual stockholder meeting where investors elected Bernadette Connaughton and Elliott Levy, M.D. as Class I directors to serve until the 2029 annual meeting. Stockholders also approved, on an advisory basis, the compensation of the company's n

Tone

Neutral 50/100

Event

Market update

Published

18 Jun 2026 20:17

Source

Stock Titan

Editas Medicine Inc (EDIT) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of Editas Medicine Inc's (EDIT) dividend and stock split history. It indicates that the company has not distributed any dividends over the past five years and has no record of stock splits. The page also displays current stock information such as

Tone

Neutral 50/100

Event

Capital return

Published

18 Jun 2026 09:40

Source

TradingKey

Editas Medicine Inc (EDIT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey attempts to provide a revenue breakdown for Editas Medicine Inc (EDIT), including business segments, regional revenue, and profit contribution. However, the company has not disclosed the relevant financial data, resulting in no information being avail

Tone

Neutral 50/100

Event

Earnings

Published

18 Jun 2026 09:40

Source

TradingKey

COMMODORE CAPITAL LP Acquires Significant Stake in Editas Medicine Inc

COMMODORE CAPITAL LP has acquired a significant 9.90% stake in Editas Medicine Inc, purchasing 16,045,802 shares at $3.08 each. This strategic investment, valued at $1.73 billion, integrates Editas Medicine, a clinical-stage biotechnology company focused on CRISPR technology, int

Tone

Neutral 50/100

Event

Deals and strategy

Published

06 Jun 2026 04:39

Source

GuruFocus

RA CAPITAL MANAGEMENT, L.P. Acquires Significant Stake in Editas Medicine Inc

RA CAPITAL MANAGEMENT, L.P. has acquired 8,889,000 shares of Editas Medicine Inc for $3.57 per share, making it a new holding and a 5.80% position in the biotechnology firm's portfolio. This strategic investment, impacting the firm's portfolio by 0.34%, highlights a continued int

Tone

Neutral 50/100

Event

Deals and strategy

Published

06 Jun 2026 04:39

Source

GuruFocus